Neurogene Inc. NGNE

NGNE Company Overview

Neurogene Inc. (Nasdaq: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. The company operates within the biotechnology and gene therapy industries, with a primary emphasis on adeno-associated virus (AAV)-based therapies and gene regulation technologies intended to address disorders of the central nervous system. Neurogene’s core objective is to develop treatments for severe pediatric neurological conditions with high unmet medical need, particularly diseases caused by single-gene mutations.

The company’s primary revenue and value drivers are its proprietary therapeutic candidates and platform technologies rather than commercial product sales, as Neurogene remains in the clinical development stage. Its lead programs include therapies targeting Rett syndrome and other rare neurodevelopmental disorders. A key differentiator for Neurogene is its development of regulated gene therapy approaches designed to control protein expression levels, an important consideration in diseases where overexpression may create safety risks. Neurogene was founded in 2018 and expanded its capabilities through internal research efforts and strategic acquisitions, including the acquisition of Neoleukin Therapeutics, which broadened aspects of its technology and public-market infrastructure.